ストックスクリーナーアプリを入手
225.28
1.50%
-3.43
プレマーケット:
229.98
4.70
+2.09%
前日終値:
$228.71
開ける：
$229.06
24時間の取引高:
444.32K
Relative Volume:
0.64
時価総額：
$13.92B
収益：
$823.12M
当期純損益:
$-253.97M
株価収益率:
-53.67
EPS:
-4.1973
ネットキャッシュフロー:
$52.82M
1週間 パフォーマンス:
+1.44%
1か月 パフォーマンス:
-1.73%
6か月 パフォーマンス:
+13.92%
1年 パフォーマンス:
+31.94%
1日の値動き範囲:
$223.79
$230.24
1週間の範囲:
$216.22
$231.78
52週間の値動き範囲:
$150.89
$250.74
Ascendis Pharma A S Stock (ASND) Company Profile
Compare ASND vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ASND
Ascendis Pharma A S
|
225.28 | 13.92B | 823.12M | -253.97M | 52.82M | -4.1973 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ascendis Pharma A S Stock (ASND) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-16 | 再開されました | Jefferies | Buy |
| 2026-01-28 | 開始されました | Barclays | Overweight |
| 2025-11-18 | 開始されました | Wolfe Research | Peer Perform |
| 2025-10-17 | 開始されました | Raymond James | Strong Buy |
| 2025-07-03 | 再開されました | Morgan Stanley | Overweight |
| 2025-05-05 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-04-16 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-01-07 | 開始されました | UBS | Buy |
| 2024-09-05 | アップグレード | Oppenheimer | Perform → Outperform |
| 2024-06-25 | アップグレード | TD Cowen | Hold → Buy |
| 2024-05-31 | 開始されました | Stifel | Buy |
| 2023-12-20 | 開始されました | Jefferies | Buy |
| 2023-06-14 | 再開されました | Credit Suisse | Neutral |
| 2023-04-05 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2023-04-04 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-03 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2022-10-20 | 開始されました | Goldman | Buy |
| 2022-08-30 | 再開されました | Berenberg | Buy |
| 2022-03-28 | 再開されました | Wedbush | Outperform |
| 2022-03-15 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-03-01 | 開始されました | Citigroup | Buy |
| 2022-02-14 | アップグレード | Oppenheimer | Perform → Outperform |
| 2022-01-06 | 開始されました | Cowen | Market Perform |
| 2021-12-08 | 開始されました | Wells Fargo | Overweight |
| 2021-10-20 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-03-30 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2021-03-11 | 再開されました | Stifel | Buy |
| 2020-12-17 | 開始されました | Berenberg | Buy |
| 2020-09-14 | 再開されました | JP Morgan | Overweight |
| 2020-03-20 | 開始されました | Oppenheimer | Outperform |
| 2019-10-11 | 開始されました | Morgan Stanley | Overweight |
| 2019-03-25 | 開始されました | Evercore ISI | Outperform |
| 2019-01-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-01-24 | アップグレード | Leerink Partners | Mkt Perform → Outperform |
| 2018-06-26 | 開始されました | Stifel | Buy |
| 2018-04-02 | 繰り返されました | Leerink Partners | Mkt Perform |
| 2017-05-11 | 開始されました | JP Morgan | Overweight |
| 2017-03-09 | ダウングレード | Leerink Partners | Outperform → Mkt Perform |
| 2017-02-09 | 開始されました | Credit Suisse | Outperform |
| 2016-09-26 | 開始されました | Wedbush | Outperform |
すべてを表示
Ascendis Pharma A S (ASND) 最新ニュース
BofA raises Ascendis Pharma stock price target on Yuviwel pricing - Investing.com
MSN Money - MSN
ASND Price Today: Ascendis Pharma A/S Stock Price, Quote & Chart | MEXC - MEXC
Ascendis will post quarterly results before markets open May 7 - Stock Titan
Net debt of Ascendis Pharma A/S – SWB:A710 - TradingView
Price to earnings ratio of Ascendis Pharma A/S – SWB:A710 - TradingView
Ascendis Pharma A/S (NASDAQ:ASND) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Ascendis Pharma A/S (NASDAQ:ASND) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat
Breakeven Is Near for Ascendis Pharma A/S (NASDAQ:ASND) - 富途牛牛
Assessing Ascendis Pharma (ASND) Valuation After Recent Share Price Uptick And Ongoing Losses - simplywall.st
Ascendis Pharma A/S (ASND): Billionaire Joe Edelman Is Bullish on This Stock - Yahoo Finance
Ascendis Pharma A/S expected to post earnings of 28 cents a shareEarnings Preview - TradingView
Ascendis Pharma A/S (ASND) Stock Analysis: Unpacking a 29.97% Potential Upside for Investors - DirectorsTalk Interviews
Calamos Advisors LLC Has $3.48 Million Holdings in Ascendis Pharma A/S $ASND - MarketBeat
Ascendis Pharma rises amid takeover speculation - MSN
Revolution, Ascendis, Arrowhead among RBC’s top M&A candidates in biotech - MSN
Ascendis Pharma gains amid takeover speculation - MSN
Morgan Stanley Upgrades Ascendis Pharma A (ASND) - MSN
Latham & Watkins Advises Ascendis Pharma on Nasdaq Ordinary Share Listing - Latham & Watkins LLP
Ascendis Pharma slides as investors digest share-structure switch and convertible-note redemption - Quiver Quantitative
Ascendis Pharma Calls Full Redemption of $575 Million 2028 Convertible Notes After Share Price Surge - The Globe and Mail
Ascendis Pharma AS (MEX:ASNDN) Stock PDF (Updated: 2026/04/27) - GuruFocus
European ADRs Edge Higher As BHP Rallies And Nokia Drops - Finimize
Ascendis Pharma Updates ISIN for Nasdaq-Listed Ordinary Shares - TipRanks
Ascendis Pharma Announces Commencement of Trading of Its Ordinary Shares on Nasdaq - Moomoo
Ascendis Pharma A/S (ASND) Stock Report: A Promising Biotech with 20.95% Potential Upside - DirectorsTalk Interviews
Ascendis Pharma Completes ADS-to-Ordinary Share Conversion and Begins Direct Nasdaq Trading - TipRanks
Ascendis Pharma A/S(NasdaqGS: ASND) dropped from NASDAQ Composite Index - marketscreener.com
How YUVIWEL’s Orphan Exclusivity and U.S. Launch Will Impact Ascendis Pharma (ASND) Investors - Sahm
Ascendis Pharma Issues New Employee Warrants as Part of Long-Term Incentive Program - The Globe and Mail
Ascendis Pharma Share Conversion Reshapes Access And Liquidity On Nasdaq - Sahm
Why Ascendis Pharma Shares Are Slumping Despite Upgrade - TipRanks
Employee warrant grants at Ascendis Pharma (NASDAQ: ASND) - Stock Titan
Ascendis Pharma Completes Strategic Trifecta with U.S. Launch of YUVIWEL and Seven-Year Orphan Exclusivity - FinancialContent
How Investors May Respond To Ascendis Pharma (ASND) Achondroplasia Combo Data And YUVIWEL Launch - Sahm
Ascendis Pharma (ASND) to List Ordinary Shares Directly on Nasdaq - Yahoo Finance
Ascendis Pharma to List Ordinary Shares Directly on Nasdaq - Sahm
Assessing Ascendis Pharma (ASND) Valuation After New COACH Trial Data And YUVIWEL Orphan Drug Exclusivity - Yahoo Finance
Biopharma bites: Ascendis' dwarfism data, funding for Life Biosciences, and more from Merck & Co., Soleno - FirstWord Pharma
Ascendis Pharma to List Ordinary Shares Directly on Nasdaq - GlobeNewswire Inc.
Ascendis Pharma (NASDAQ: ASND) to swap ADSs for ordinary shares in Nasdaq direct listing - Stock Titan
Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States - Yahoo Finance
Ascendis Pharma A/S (ASND) stock price, news, quote and history - Yahoo Finance Singapore
Ascendis Pharma A/S (ASND) Reports Positive Week 52 Data from Phase 2 New InsiGHTS Trial - Yahoo Finance
Cantor Fitzgerald reiterates Ascendis Pharma stock rating at overweight - Investing.com
Ascendis Pharma closes warrant exercise window and increases share capital - Investing.com
Ascendis Pharma Trial Wins And Valuation Gap Draw Investor Attention - Yahoo Finance
Revolution, Ascendis Named Top Buyout Targets as Industry Awaits The Big One - BioSpace
Ascendis Pharma (ASND) CFO lists warrants, RSUs and shares - Stock Titan
Ascendis Pharma (ASND) Is Down 5.8% After New Two-Year YUVIWEL Achondroplasia Data Release – Has The Bull Case Changed? - Sahm
Avoro Capital Advisors LLC Has $1.02 Billion Stock Holdings in Ascendis Pharma A/S $ASND - Defense World
Ascendis Pharma A S (ASND) 財務データ
収益
当期純利益
現金流量
EPS
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):